Form 4: Shattuck Labs Director Granted Future Stock Options

Shattuck Labs, Inc. director Mona Ashiya was granted 66,300 stock options with an exercise price of $0.99, vesting over three years starting August 28, 2025.

Summary

• Mona Ashiya, a Director of Shattuck Labs, Inc. (STTK), was granted stock options to purchase 66,300 shares of common stock.
• The options have an exercise price of $0.99 per share.
• The grant date for these options is August 28, 2025.
• The options will vest in three equal annual installments on each of the first three anniversaries of August 28, 2025, contingent on Ms. Ashiya's continued service to the Issuer.
• The expiration date for these options is August 28, 2035.
• Ms. Ashiya is obligated to transfer any securities issued under these stock options, or their economic benefit, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will then provide them to OrbiMed Private Investments IX, LP.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. No significant positive or negative operational news is present.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value creation of Shattuck Labs, Inc.

Risks

• The obligation to transfer the economic benefit of the options to OrbiMed entities introduces a layer of complexity regarding the direct personal incentive for the director, though it aligns with the interests of the OrbiMed fund.

Future Outlook

This filing does not contain forward-looking statements regarding Shattuck Labs, Inc.'s operational or financial performance, focusing solely on an individual's equity compensation.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term value creation. The specific arrangement with OrbiMed reflects the director's affiliation with a significant institutional investor in the sector.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across many industries, including biotech, to align interests with shareholders.
• The vesting schedule of three equal annual installments is a common structure for equity compensation, promoting retention and long-term commitment.
• The obligation to transfer benefits to an associated investment fund (OrbiMed) is less common for individual directors but typical when the director represents a specific institutional investor on the board, such as in the case of venture capital or private equity-backed companies.

Corporate Governance

Related Party Transactions

• The reporting person, Mona Ashiya, is obligated to transfer any securities issued under the stock options, or their economic benefit, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure such benefits are provided to OrbiMed Private Investments IX, LP. This indicates a related party arrangement, likely due to Ms. Ashiya's affiliation with OrbiMed.

Stakeholder Impact

• Shareholders: The grant of options to a director, even with the OrbiMed transfer clause, generally aligns the interests of a key board member (and a significant institutional investor) with the long-term performance of the company.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest in three equal annual installments on the first three anniversaries of August 28, 2025, subject to continued service.

Key Dates

Keywords

Shattuck Labs, STTK, Mona Ashiya, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, OrbiMed, Vesting Schedule